About TransMedics Group, Inc.
https://www.transmedics.comTransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.
CEO
Waleed H. Hassanein
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 173
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Canaccord Genuity
Buy
Needham
Buy
Oppenheimer
Outperform
Piper Sandler
Overweight
Morgan Stanley
Equal Weight
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:5.33M
Value:$756.87M
FMR LLC
Shares:5.06M
Value:$718.94M
VANGUARD GROUP INC
Shares:3.61M
Value:$511.85M
Summary
Showing Top 3 of 426
About TransMedics Group, Inc.
https://www.transmedics.comTransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $143.82M ▼ | $61.27M ▲ | $24.32M ▼ | 16.91% ▼ | $0.71 ▼ | $33.37M ▼ |
| Q2-2025 | $157.37M ▲ | $60.02M ▼ | $34.91M ▲ | 22.18% ▲ | $1.03 ▲ | $46.39M ▲ |
| Q1-2025 | $143.54M ▲ | $60.78M ▼ | $25.68M ▲ | 17.89% ▲ | $0.76 ▲ | $36.27M ▲ |
| Q4-2024 | $121.62M ▲ | $63.37M ▲ | $6.86M ▲ | 5.64% ▲ | $0.2 ▲ | $16.24M ▲ |
| Q3-2024 | $108.76M | $56.92M | $4.22M | 3.88% | $0.13 | $13.04M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $466.17M ▲ | $946.03M ▲ | $590.83M ▲ | $355.2M ▲ |
| Q2-2025 | $400.57M ▲ | $890.52M ▲ | $572.42M ▲ | $318.1M ▲ |
| Q1-2025 | $310.14M ▼ | $837.53M ▲ | $571.22M ▼ | $266.31M ▲ |
| Q4-2024 | $336.65M ▲ | $804.08M ▲ | $575.47M ▼ | $228.6M ▲ |
| Q3-2024 | $330.09M | $785.57M | $575.65M | $209.92M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $24.32M ▼ | $69.57M ▼ | $-7.62M ▲ | $3.64M ▼ | $65.6M ▼ | $61.95M ▼ |
| Q2-2025 | $34.91M ▲ | $91.61M ▲ | $-9.07M ▲ | $7.09M ▲ | $90.43M ▲ | $82.53M ▲ |
| Q1-2025 | $25.68M ▲ | $-2.85M ▼ | $-27.04M ▼ | $3.03M ▲ | $-26.51M ▼ | $-29.89M ▼ |
| Q4-2024 | $6.86M ▲ | $19.66M ▲ | $-13.61M ▲ | $1.19M ▼ | $6.56M ▲ | $6.06M ▲ |
| Q3-2024 | $4.22M | $6.86M | $-47.76M | $7.86M | $-32.66M | $-41.35M |
Revenue by Products
| Product | Q4-2024 | Q2-2025 | Q1-2025 | Q3-2025 |
|---|---|---|---|---|
 Product | $70.00M ▲ | $100.00M ▲ | $90.00M ▼ | $90.00M ▲ |
 Service | $0 ▲ | $60.00M ▲ | $60.00M ▲ | $60.00M ▲ |
Revenue by Geography
| Region | Q3-2022 | Q4-2022 | Q1-2023 | Q2-2023 |
|---|---|---|---|---|
 Other Countries | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 UNITED STATES | $20.00M ▲ | $30.00M ▲ | $40.00M ▲ | $0 ▼ |
CEO
Waleed H. Hassanein
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 173
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Canaccord Genuity
Buy
Needham
Buy
Oppenheimer
Outperform
Piper Sandler
Overweight
Morgan Stanley
Equal Weight
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:5.33M
Value:$756.87M
FMR LLC
Shares:5.06M
Value:$718.94M
VANGUARD GROUP INC
Shares:3.61M
Value:$511.85M
Summary
Showing Top 3 of 426